ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus

Graciela S. Alarcón, MD, MPH, MACR  |  December 6, 2025

This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.

Filed under:ACR ConvergenceConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNLupus nephritis supplementresearch reviews

B Cell-Depleting Therapy in SLE & Lupus Nephritis

Katie Robinson  |  November 22, 2025

“B cells are central orchestraters of autoimmune disease by contributing to autoantibody production, antigen presentation and cytokine production,” says Georg Schett, MD, head of the Department of Medicine 3 (Rheumatology and Immunology) of the Friedrich-Alexander University Erlangen-Nürnberg, Germany. “B cells can be inhibited by monoclonal antibodies and chimeric antigen receptor (CAR) expressing cells.” Dr. Schett…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:B cell depleting therapyB cell depletionCAR-T cell therapyCD19 CAR-T cell treatmentImmunologyLupus nephritis

Advances in Giant Cell Arteritis

Philip Seo, MD, MHS  |  November 14, 2025

Dr. Philip Seo highlights the latest research into the assessment and treatment of giant cell arteritis presented during ACR Convergence 2025.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:AAV FocusRheumACR Convergence 2025ANCA-Associated Vasculitisgiant cell arteritis (GCA)GlucocorticoidsimagingMagnetic resonance imaging (MRI)taperingupadacitinib

Secrets & Pearls of Rheumatology at ACR Convergence 2025

Mithu Maheswaranathan, MD  |  November 12, 2025

Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.

Filed under:ACR ConvergenceMeeting ReportsMyositisOther Rheumatic ConditionsSjögren’s DiseaseSystemic Lupus ErythematosusVasculitis Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNconnective tissue diseaseLupusLupus nephritismyositisRaynaud’s phenomenonRheumatic DiseaseSjögren's Diseasesystemic lupus erythematosus (SLE)

No Longer as Vexing: The Role of Somatic Mutations in Rheumatic Diseases

Jason Liebowitz, MD, FACR  |  November 7, 2025

At this ACR Convergence 2025 session, two experts discussed VEXAS & the role that genetic sequencing should play in the practice of a rheumatologist.

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2025genetic sequencingVEXASVEXAS syndrome

The Microbiome’s Impact on Rheumatoid Arthritis & Drug Response

Ruth Jessen Hickman, MD  |  November 7, 2025

The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.

Filed under:ACR ConvergenceConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR Convergence 2025autoimmunitygut microbiomeMethotrexateMicrobiomePathogenesisPharmacomicrobiomics

JIA: The Transition to Adult Care

Ruth Jessen Hickman, MD  |  November 5, 2025

Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2025JIAJIA-associated uveitisjuvenile idiopathic arthritis (JIA)pediatric arthritistemporomandibular joint (TMJ)

Meet Incoming ARP President Rebecca Cleveland

Leslie Mertz, PhD  |  October 29, 2025

Incoming ARP President Dr. Rebecca Cleveland discusses her plans for advocacy, ACR/ARP collaboration, & tackling workforce shortages in rheumatology.

Filed under:ACR ConvergenceInterprofessional PerspectivePractice SupportProfilesWorkforce Tagged with:ACR Convergence 2025advanced practice provider (APP)ARP presidentAssociation of Rheumatology Professionals (ARP)Dr. Rebecca ClevelandepidemiologyOsteoarthritisVolunteerismWorkforce

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 28, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Filed under:ACR ConvergenceAmerican College of RheumatologyGout and Crystalline ArthritisMeeting ReportsOther Rheumatic ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ACR Convergence 2025GoutLupusmacrophage activation syndromeMethotrexatesystemic lupus erythematosus (SLE)Vasculitis

FDA Approves 2 More Denosumab Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  October 27, 2025

The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsdenosumabdenosumab-nxxpFDA approvalOsteoporosisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences